Investigative plan of action

 

As more companies store information electronically, there is an increased need for digital forensics to discover the trails of illegal or malicious acts. In this task, you will use the scenario to develop an investigative plan of action that will prepare your investigative team to conduct an analysis on the gathered evidence.
SCENARIO
An oil company’s senior management has reason to suspect that John Smith, one of the company’s mechanical engineers allegedly took information that was clearly identified as proprietary. The company’s legal office has requested digital evidence regarding the potential violation of company policy, which prohibits the sharing of proprietary information without prior approval. The employee was not authorized to access proprietary information. All employees sign nondisclosure agreements (NDAs) and acceptable use policies (AUPs). Senior management and the legal office have approved this request.

You are a member of the investigative team that has been asked to develop an investigative plan of action.
REQUIREMENTS
Your submission must be your original work. No more than a combined total of 30% of the submission and no more than a 10% match to any one individual source can be directly quoted or closely paraphrased from sources, even if cited correctly. The originality report that is provided when you submit your task can be used as a guide.

You must use the rubric to direct the creation of your submission because it provides detailed criteria that will be used to evaluate your work. Each requirement below may be evaluated by more than one rubric aspect. The rubric aspect titles may contain hyperlinks to relevant portions of the course.

Tasks may not be submitted as cloud links, such as links to Google Docs, Google Slides, OneDrive, etc., unless specified in the task requirements. All other submissions must be file types that are uploaded and submitted as attachments (e.g., .docx, .pdf, .ppt).

A. Create an investigative plan of action based on forensic best practices or standards that your team will implement by doing the following:

1. Discuss the strategy that your team will use to both maximize the collection of evidence and minimize the impact on the organization.

2. Describe the tools and techniques your team will use in evidence gathering, preparation, and analysis.

3. Describe how your team will collect and preserve required evidence, using standardized and accepted procedures.

4. Describe how your team will examine the seized evidence to determine which items are related to the suspected violation of company policy.

5. Discuss an approach that your team will use to draw conclusions based on the digital evidence that supports the claim of a policy violation.

6. Discuss how the case details and conclusions should be presented to senior management.

B. Acknowledge sources, using in-text citations and references, for content that is quoted, paraphrased, or summarized.

C. Demonstrate professional communication in the content and presentation of your submission.

Sample Solution

Several main genetic mutational patterns of both resistance and cross-resistance can develop with using nucleoside (or nucleotide) reverse transcriptase inhibitors, as well as thymidine analog mutations, such as TAMs, and non-thymidine mutations, for example, M184V and K65R. In treated patients, TAMs can develop in an organized way, and their accumulation is identified with an increasing level of resistance (Boucher et al., 1992). Commonly, TAMs were chosen by stavudine- and zidovudine-based regimens, yet evidence demonstrates that these mutations are additionally connected to resistance to other NRTI agent (Shafer, 2002).

Actually, there is wide cross-resistance inside the NRTI class. The size of phenotypic and clinical resistance to different NRTIs is by all accounts identified with the number of TAMs. Therefore, particular patterns of TAMs could affect treatment responses differently. In contrast, the K65R mutations are linked with all cross-resistance agents from this class aside from zidovudine. Having low genetic barrier NRTI analogs, have need of a single point mutation to give high levels of resistance, including emtricitabine and lamivudine, while most non deoxycytidine NRTIs, like, didanosine, abacavir, thymidine analogs, and tenofovir (the nucleotide reverse transcriptase inhibitor), are associated with moderate genetic barriers for resistance development.

In spite of the various advantages of NNRTI on virologic results, their utilization is constrained by their low genetic barrier to resistance. First generation of NNRTIs (nevirapine and efavirenz) resistance is described by a quick selection of viruses which have one or a few mutations in the gene of reverse transcriptase that give high level of resistance to these agents. A mutation in the reverse transcriptase enzyme, specifically single-point mutation, is frequently enough to present high-level loss of medication affinity that is connected with significant clinically phenotypic resistance. In spite of their diverse structures, efavirenz and nevirapine show marked cross-resistance

This question has been answered.

Get Answer
WeCreativez WhatsApp Support
Our customer support team is here to answer your questions. Ask us anything!
👋 Hi, Welcome to Compliant Papers.